近日,康哲药业控股有限公司(简称“康哲药业”)正式宣布,其自主研发的靶向INHBE的小干扰RNA(siRNA)药物CMS-D008注射液,成功获得国家药品监督管理局药品审评中心(CDE)签发的新药临床试验(IND)批件,获批开展用于治疗超重或肥胖人群的临床试验。CMS-D008注射液是一款皮下注射的siRNA药物,核心机制是通过RNA干扰技术(RNAi)精准抑制肝脏表达的INHBE基因(编码激活素...
Source Link近日,康哲药业控股有限公司(简称“康哲药业”)正式宣布,其自主研发的靶向INHBE的小干扰RNA(siRNA)药物CMS-D008注射液,成功获得国家药品监督管理局药品审评中心(CDE)签发的新药临床试验(IND)批件,获批开展用于治疗超重或肥胖人群的临床试验。CMS-D008注射液是一款皮下注射的siRNA药物,核心机制是通过RNA干扰技术(RNAi)精准抑制肝脏表达的INHBE基因(编码激活素...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.